{"id":579686,"date":"2021-12-20T16:56:01","date_gmt":"2021-12-20T16:56:01","guid":{"rendered":"https:\/\/www.abnewswire.com\/pressreleases\/?p=579686"},"modified":"2021-12-20T16:56:01","modified_gmt":"2021-12-20T16:56:01","slug":"postherpetic-neuralgia-clinical-and-nonclinical-trials-emerging-pipeline-therapies-and-treatment-algorithm-key-companies-lifemax-laboratories-novartis-teva-pharma-and-others","status":"publish","type":"post","link":"https:\/\/www.abnewswire.com\/pressreleases\/postherpetic-neuralgia-clinical-and-nonclinical-trials-emerging-pipeline-therapies-and-treatment-algorithm-key-companies-lifemax-laboratories-novartis-teva-pharma-and-others_579686.html","title":{"rendered":"Postherpetic Neuralgia &#8211; Clinical and Non-Clinical Trials, Emerging Pipeline Therapies, and Treatment Algorithm | Key Companies &#8211; LifeMax Laboratories, Novartis, Teva Pharma, and Others"},"content":{"rendered":"<div style=\"float:right; width:250px; padding:8px 10px 10px 10px;\">\n<div><a href=\"https:\/\/www.abnewswire.com\/uploads\/1585677425.jpeg\" style=\"border:none !important;\" target=\"_blank\" rel=\"nofollow\" ><img loading=\"lazy\" decoding=\"async\" class=\"alignnone size-medium wp-image-29\" title=\"Postherpetic Neuralgia - Clinical and Non-Clinical Trials, Emerging Pipeline Therapies, and Treatment Algorithm | Key Companies - LifeMax Laboratories, Novartis, Teva Pharma, and Others\" src=\"https:\/\/www.abnewswire.com\/uploads\/1585677425.jpeg\" alt=\"Postherpetic Neuralgia - Clinical and Non-Clinical Trials, Emerging Pipeline Therapies, and Treatment Algorithm | Key Companies - LifeMax Laboratories, Novartis, Teva Pharma, and Others\" width=\"225\" height=\"225\" style=\"padding:0px 0px 10px 10px; border:0 solid !important;\" \/><\/a><\/div>\n<div class=\"quotes\">\n<div>Delveinsight Business Research LLP<\/div>\n<\/div>\n<\/div>\n<div style=\"font-style:italic; padding:8px 0px;\">&#8220;Postherpetic Neuralgia Pipeline Insight, 2021&#8221; report by DelveInsight outlines comprehensive insights of present clinical development scenario and growth prospects across the Postherpetic Neuralgia Market.<\/div>\n<p style=\"text-align: justify;\" dir=\"ltr\">The <strong>Postherpetic Neuralgia Pipeline<\/strong> report embraces in-depth commercial and clinical assessment of the Postherpetic Neuralgia pipeline products from the pre-clinical developmental phase to the marketed phase.&nbsp;<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">The report covers a detailed description of the drug including mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, <strong>Postherpetic Neuralgia collaborations<\/strong>, mergers, acquisition, funding, designations, and other product-related details.<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><img decoding=\"async\" style=\"display: block; margin-left: auto; margin-right: auto;\" title=\"Postherpetic Neuralgia Pipeline Analysis\" src=\"https:\/\/www.abnewswire.com\/uploads\/5a03321adde73d1cda2e553329c4f9fb.jpg\" alt=\"Postherpetic Neuralgia Pipeline Analysis\" \/><\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/report-store\/postherpetic-neuralgia-pipeline-insight?utm_source=abnewswire&amp;utm_medium=pressrelease&amp;utm_campaign=rpr\" target=\"_blank\"><strong>Postherpetic Neuralgia Pipeline Analysis<\/strong><\/a><\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><strong>The report provides insights into:&nbsp;<\/strong><\/p>\n<ul style=\"text-align: justify;\">\n<li dir=\"ltr\">\n<p dir=\"ltr\">The report provides detailed insights about companies that are developing therapies for the <strong>treatment of Postherpetic Neuralgia<\/strong> with aggregate therapies developed by each company for the same.<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for the Postherpetic Neuralgia Treatment.<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\"><strong>Postherpetic Neuralgia key companies<\/strong> involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\"><strong>Postherpetic Neuralgia Drugs<\/strong> under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.&nbsp;<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement, and financing details for future advancement of the Postherpetic Neuralgia market.<\/p>\n<\/li>\n<\/ul>\n<p style=\"text-align: justify;\" dir=\"ltr\">The report is built using data and information traced from the researcher&#8217;s proprietary databases, company\/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company\/university websites and industry-specific third-party sources, etc.&nbsp;&nbsp;<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/report-store\/postherpetic-neuralgia-pipeline-insight?utm_source=abnewswire&amp;utm_medium=pressrelease&amp;utm_campaign=rpr\" target=\"_blank\"><strong>Postherpetic Neuralgia Therapeutics Landscape<\/strong><\/a><\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><em>At present, some of the key companies at the global level are actively working toward the development of potential therapies for Postherpetic Neuralgia in order to overcome the unmet medical needs of the currently used therapeutics.<\/em><\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><strong>Key companies in the Postherpetic Neuralgia Market include:<\/strong><\/p>\n<ul style=\"text-align: justify;\">\n<li dir=\"ltr\">\n<p dir=\"ltr\">LifeMax Laboratories<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">Novartis Pharmaceuticals<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">Teva Pharmaceutical<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">GlaxoSmithKline<\/p>\n<\/li>\n<\/ul>\n<p style=\"text-align: justify;\" dir=\"ltr\">And many others.<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><strong>Postherpetic Neuralgia Therapies covered in the report include:<\/strong><\/p>\n<ul style=\"text-align: justify;\">\n<li dir=\"ltr\">\n<p dir=\"ltr\">LAT-NP-001<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">EMA401<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">TV-45070<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">HORIZANT<\/p>\n<\/li>\n<\/ul>\n<p style=\"text-align: justify;\" dir=\"ltr\">And many more.<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><strong>Request for Sample Pages @ <a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/sample-request\/postherpetic-neuralgia-pipeline-insight?utm_source=abnewswire&amp;utm_medium=pressrelease&amp;utm_campaign=rpr\" target=\"_blank\">Postherpetic Neuralgia Emerging Therapies and Key Companies<\/a><\/strong><\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><strong>Report Highlights<\/strong><\/p>\n<ul style=\"text-align: justify;\">\n<li dir=\"ltr\">\n<p dir=\"ltr\">A better understanding of disease pathogenesis contributing to the development of <strong>novel therapeutics for Postherpetic Neuralgia<\/strong>.&nbsp;&nbsp;&nbsp;&nbsp;<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">In the coming years, the Postherpetic Neuralgia market is set to change due to the rising awareness of the disease, and incremental healthcare spending across the world; which would expand the size of the market to enable the drug manufacturers to penetrate more into the market.&nbsp;<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">The companies and academics are working to assess challenges and seek opportunities that could influence <strong>Postherpetic Neuralgia Research &amp; Development<\/strong>. The therapies under development are focused on novel approaches to treat\/improve the disease condition.<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">A detailed portfolio of major pharma players who are involved in fueling the <strong>Postherpetic Neuralgia treatment market<\/strong>. Several potential therapies for Postherpetic Neuralgia are under investigation. With the expected launch of these emerging therapies, it is expected that there will be a significant impact on the Postherpetic Neuralgia market size in the coming years.&nbsp;&nbsp;<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">Our in-depth analysis of the <strong>Postherpetic Neuralgia pipeline assets<\/strong> (in early-stage, mid-stage, and late stage of development) includes therapeutic assessment and comparative analysis. This will support the clients in the decision-making process regarding their therapeutic portfolio by identifying the overall scenario of the research and development activities.&nbsp;<\/p>\n<\/li>\n<\/ul>\n<p style=\"text-align: justify;\" dir=\"ltr\"><strong>Download Sample Pages @ <a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/sample-request\/postherpetic-neuralgia-pipeline-insight?utm_source=abnewswire&amp;utm_medium=pressrelease&amp;utm_campaign=rpr\" target=\"_blank\">Postherpetic Neuralgia Therapeutics Assessment<\/a><\/strong><\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><strong>Table of Content<\/strong><\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">1. Report Introduction<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">2. Postherpetic Neuralgia&nbsp;<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">3. Postherpetic Neuralgia Current Treatment Patterns<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">4. Postherpetic Neuralgia &#8211; DelveInsight&#8217;s Analytical Perspective<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">5. Therapeutic Assessment<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">6. Postherpetic Neuralgia Late Stage Products (Phase-III)<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">7. Postherpetic Neuralgia Mid Stage Products (Phase-II)<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">8. Early Stage Products (Phase-I)<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">9. Pre-clinical Products and Discovery Stage Products<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">10. Inactive Products<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">11. Dormant Products<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">12. Postherpetic Neuralgia Discontinued Products<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">13. Postherpetic Neuralgia Product Profiles<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">14. Postherpetic Neuralgia Key Companies<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">15. Postherpetic Neuralgia Key Products<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">16. Dormant and Discontinued Products<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">17. Postherpetic Neuralgia Unmet Needs<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">18. Postherpetic Neuralgia Future Perspectives<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">19. Postherpetic Neuralgia Analyst Review&nbsp;&nbsp;<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">20. Appendix<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">21. Report Methodology<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><strong>*The table of contents is not exhaustive; the final content may vary.&nbsp;<\/strong><\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><strong>Visit to get the sample report:&nbsp;<a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/sample-request\/postherpetic-neuralgia-pipeline-insight?utm_source=abnewswire&amp;utm_medium=pressrelease&amp;utm_campaign=rpr\" target=\"_blank\">https:\/\/www.delveinsight.com\/sample-request\/postherpetic-neuralgia-market<\/a><\/strong><\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><strong>About DelveInsight<\/strong><\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">DelveInsight is a leading Business Consultant, and Market Research Firm focused exclusively on life sciences. It supports pharma companies by providing end-to-end comprehensive solutions to improve their performance.<\/p>\n<p><span style='font-size:18px !important;'>Media Contact<\/span><br \/><strong>Company Name:<\/strong> <a href=\"https:\/\/www.abnewswire.com\/companyname\/delveinsight.com_56421.html\" rel=\"nofollow\">DelveInsight Business Research LLP<\/a><br \/><strong>Contact Person:<\/strong> Shruti Thakur<br \/><strong>Email:<\/strong> <a href=\"https:\/\/www.abnewswire.com\/email_contact_us.php?pr=postherpetic-neuralgia-clinical-and-nonclinical-trials-emerging-pipeline-therapies-and-treatment-algorithm-key-companies-lifemax-laboratories-novartis-teva-pharma-and-others\" rel=\"nofollow\">Send Email<\/a><br \/><strong>Phone:<\/strong> 09650213330<br \/><strong>Address:<\/strong>304 S. Jones Blvd #2432  <br \/><strong>City:<\/strong> Las Vegas<br \/><strong>State:<\/strong> NV<br \/><strong>Country:<\/strong> United States<br \/><strong>Website:<\/strong> <a href=\"https:\/\/www.delveinsight.com\/\" target=\"_blank\" rel=\"nofollow\">https:\/\/www.delveinsight.com\/<\/a><\/p>\n<p><object type=\"text\/html\" data=\"https:\/\/www.delveinsight.com\/\" style=\"width:900px; height:400px;\"><\/object><img decoding=\"async\" src=\"https:\/\/www.abnewswire.com\/press_stat.php?pr=postherpetic-neuralgia-clinical-and-nonclinical-trials-emerging-pipeline-therapies-and-treatment-algorithm-key-companies-lifemax-laboratories-novartis-teva-pharma-and-others\" alt=\"\" width=\"1px\" height=\"1px\" \/><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Delveinsight Business Research LLP &#8220;Postherpetic Neuralgia Pipeline Insight, 2021&#8221; report by DelveInsight outlines comprehensive insights of present clinical development scenario and growth prospects across the Postherpetic Neuralgia Market. The Postherpetic Neuralgia Pipeline report embraces in-depth commercial and clinical assessment of &hellip; <a href=\"https:\/\/www.abnewswire.com\/pressreleases\/postherpetic-neuralgia-clinical-and-nonclinical-trials-emerging-pipeline-therapies-and-treatment-algorithm-key-companies-lifemax-laboratories-novartis-teva-pharma-and-others_579686.html\">Continue reading <span class=\"meta-nav\">&rarr;<\/span><\/a><\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[435,405,406,403,404],"tags":[],"class_list":["post-579686","post","type-post","status-publish","format-standard","hentry","category-Europe","category-Health-Medicine","category-Pharmaceuticals-Biotech","category-UK","category-US"],"_links":{"self":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts\/579686","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/comments?post=579686"}],"version-history":[{"count":0,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts\/579686\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/media?parent=579686"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/categories?post=579686"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/tags?post=579686"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}